500 patients67,039 observations150 daysLIVE
← Patients

Patient P-03300

Synthetic patientONX-7 · Day 150 · 35–44 · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Favorable
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Stable
Discontinuation risk
73%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 ONX-7 started — Baseline state S14
  2. Day 60 Trajectory diverged from prediction — Observed response fell below the model's expected path.
  3. Day 69 GI-04 recommended — GI Support Protocol GI-04
  4. Day 70 Patient accepted — Started GI-04 in the companion
  5. Day 78 GI symptom burden −38% vs expected — GI Support Protocol GI-04
  6. Day 84 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 60.

Primary contributors, last 14 days
  • GI instability+13
  • Inflammatory activity+5
  • Nutritional resilience-4

What helped?

  • GI Support Protocol GI-04Day 69
    Result: symptom burden −38%
LIFE OS recommendation
Dosing / Timing Recommendation DT-01
70%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 80% showed improvement
  • median effect visible after 5 days
View similar patientsSimulateAdd to intervention cohortAll evidence

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Energy level
Daily log
4.2/10
stable · +0.0 vs previous 14 d
Stress level
Daily log
5.9/10
stable · +0.0 vs previous 14 d
Pessimism score
Daily log
5.3/10
worsening · +0.3 vs previous 14 d
Sleep quality
Wearable
46.1/100
stable · -0.8 vs previous 14 d
Libido
Daily log
4/10
stable · -0.0 vs previous 14 d
HRV
Wearable
44.7 ms
stable · -1.0 vs previous 14 d
Toxicity
Blood
29.8/100
improving · -1.4 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards failing · 41 from the failing basin, 47 from restoration.

Would help
  • ME-01 Monitoring Escalation
    100% improved among 11 similar · onset 3 d · confidence 73%
  • DT-01 Dosing / Timing Recommendation
    80% improved among 10 similar · onset 5 d · confidence 73%
  • CR-01 Clinician Review
    100% improved among 5 similar · onset 5 d · confidence 73%
  • More protein
    GI -5.2 next day on high-intake days · n 17
Would not help
  • AD-05 Adherence Support
    only 25% improved among 12 similar
  • Keep fat low
    GI +6.4 next day on high-intake days · n 21
  • Keep histamine low
    GI +5.2 next day on high-intake days · n 21
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Dietary fat load
    +6.4detractor · 95%
  • Histamine load
    +5.2detractor · 95%
  • Protein
    -5.2supporter · 95%
  • Lactose
    +1.4no signal · 27%
  • Alcohol
    +0.9no signal · 16%
  • Caffeine
    -0.8no signal · 17%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Mucosal barrier integrity ↓80
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 47 and rising
  • Inflammatory signalling ↑50
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • BloodInflammatory load index 41
  • Butyrate / short-chain fatty acid production ↓35
    • MicrobiomeButyrate capacity 40/100
  • Autonomic recovery ↓25
    • WearableResting HR 74 bpm
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Normal metabolizer
    Expected exposure
Microbiome
Shannon diversity 2.6 · butyrate capacity 40/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiNormal
  • Bacteroides fragilisNormal
  • Bifidobacterium longumLow
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
46 ms
Sleep
6.8 h
Steps
6,657
Resting HR
72 bpm
Daily log: GI score 47, nutritional resilience 52, adherence 51.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • Keep the current walking rhythm
  • Keep the sleep window steady
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Sort by similaritySort by interventionSort by outcomeSort by stateSort by response
PatientSimilarityBaselineInterventionOutcomeResponse today
P-0318124%S03——75
P-0311326%S08NP-02no change73
P-0302324%S16——73
P-0341224%S14——72
P-0331524%S08——72
P-0334927%S11——71
P-0334626%S17GI-04improved71
P-0320133%S15GI-04improved68
P-0325225%S13SC-12improved68
P-0331126%S06——68
P-0345625%S18——68
P-0321424%S18——68